WESTFORD, Mass., Dec. 5, 2016 /PRNewswire/ -- Cynosure, Inc.
(NASDAQ: CYNO) today announced it has been recognized as one of
Deloitte's Technology Fast 500™, a ranking of the 500
fastest-growing technology, media, telecommunications, life
sciences and energy tech companies in North America. Cynosure received the award for
its strong 121% revenue growth between the 2012 and 2015 fiscal
years.
"Cynosure is honored to be recognized as one of the
fastest-growing companies in North
America," said Michael Davin,
the Company's president and CEO. "We continue to generate record
revenues, profitable sales growth, expanded margins and positive
operating cash flow. This success is due in large part to the
demand for our leading-edge aesthetic treatment products, such as
SculpSure®, PicoSure® and MonaLisa Touch®. We are grateful for the
hard work of the entire Cynosure team and confident in our strategy
as we strive for continued excellence."
For a complete list of the ranking and more information on
Deloitte's Technology Fast 500™, click here.
About Deloitte's 2016 Technology Fast 500™
Deloitte's Technology Fast 500 provides a ranking of the fastest
growing technology, media, telecommunications, life sciences and
energy tech companies – both public and private – in North America. Technology Fast 500 award
winners are selected based on percentage fiscal year revenue growth
from 2012 to 2015.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least $50,000
USD, and current-year operating revenues of at least
$5 million USD. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North
America.
As used in this document, "Deloitte" means Deloitte LLP and its
subsidiaries. Please see www.deloitte.com/us/about for a detailed
description of the legal structure of Deloitte LLP and its
subsidiaries. Certain services may not be available to attest
clients under the rules and regulations of public accounting.
About Cynosure, Inc.
Cynosure develops, manufactures and markets aesthetic treatment
systems that enable plastic surgeons, dermatologists and other
medical practitioners to perform non-invasive and minimally
invasive procedures to remove hair, treat vascular and benign
pigmented lesions, remove multi-colored tattoos, revitalize the
skin, reduce fat through laser lipolysis, reduce cellulite, clear
nails infected by toe fungus, ablate sweat glands and improve
women's health. The Company also markets radiofrequency (RF)
energy-sourced medical devices for precision surgical applications
such as facial plastic and general surgery, gynecology, ear, nose,
and throat procedures, ophthalmology, oral and maxillofacial
surgery, podiatry and proctology. Cynosure's product portfolio is
composed of a broad range of energy sources including Alexandrite,
diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense
pulsed light and RF technology. Cynosure sells its products
globally under the Cynosure, Palomar, ConBio and Ellman brand names
through a direct sales force in the
United States, Canada,
France, Morocco, Germany, Spain, the United
Kingdom, Australia,
China, Japan and Korea, and through international
distributors in approximately 120 other countries. For corporate or
product information, visit Cynosure's website at
www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Cynosure, Inc., including Cynosure's
expectations with respect to timing and success of product launches
and expansions, regulatory clearances and international
registrations, as well as other statements containing the words,
"believes," "looks forward," "anticipates," "plans," "expects,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including the market price of Cynosure's stock
prevailing from time to time, the nature of other investment
opportunities presented to the Company from time to time, the
Company's cash flow from operations, levels of demand for
procedures performed with Cynosure products and for Cynosure
products themselves, competition in the aesthetic laser industry,
general business and economic conditions, effects of acquisitions
that Cynosure has made or may make, Cynosure's ability to develop
and commercialize new products, Cynosure's reliance on sole source
suppliers, the inability to accurately predict the timing or
outcome of regulatory decisions, and economic, market,
technological and other factors described in Item 1A of Part II
(Risk Factors) of our Quarterly Report on Form 10-Q for the three
months ended September 30, 2016. In
addition, the forward-looking statements included in this press
release represent Cynosure's views as of the date of this press
release. Cynosure anticipates that subsequent events and
developments will cause its views to change. However, although
Cynosure may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. These forward-looking statements should not be relied
upon as representing Cynosure's views as of any date after the date
of this press release.
Contact:
Scott Solomon
Senior Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cynosure-recognized-among-deloittes-2016-technology-fast-500-300372726.html
SOURCE Cynosure, Inc.
